Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -48.1% | -9.6% | 47.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95.9% | 98.3% | 97% | 93% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.5% | -31.2% | -34.1% | -64.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -49.8% | -23.6% | -27% | -44.2% |
| EPS Diluted | -0.057 | -0.055 | -0.076 | -0.089 |
| % Growth | -2.7% | 27% | 15% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |